REPRODUKTIV TIZIM XAVFLI O‘SMALARI BILAN OG‘RIGAN BEMORLARDA KIMYOVIY TERAPIYA JARAYONIDA PSIXOEMOTSIONAL HOLAT VA HAYOT SIFATINING KLINIK-PSIXOPATOLOGIK XUSUSIYATLARI
Kalit so‘zlar:
reproduktiv tizim, xavfli o‘sma, kimyoviy terapiya, psixoemotsional holat, hayot sifatiAbstrak
Ushbu maqolada reproduktiv tizim xavfli o‘smalari bilan og‘rigan bemorlarda kimyoviy terapiya jarayonida psixoemotsional holat va hayot sifatining klinik-psixopatologik xususiyatlari o‘rganilgan. Tadqiqotning maqsadi kimyoviy terapiya olayotgan bemorlarda xavotir, depressiv holatlar va boshqa psixoemotsional buzilishlarning namoyon bo‘lish darajasini aniqlash hamda ularning hayot sifati ko‘rsatkichlari bilan o‘zaro bog‘liqligini baholashdan iborat. Tadqiqotda klinik-psixopatologik, psixodiagnostik va statistik tahlil usullaridan foydalanilgan. Bemorlarning ruhiy holati, psixoemotsional zo‘riqish darajasi, ijtimoiy moslashuvi va hayot sifati ko‘rsatkichlari kompleks baholangan. Olingan natijalar kimyoviy terapiya jarayonida psixoemotsional buzilishlarning kuchayishi bemorlarning jismoniy faolligi, emotsional holati, ijtimoiy faoliyati va umumiy hayot sifati pasayishi bilan bog‘liq ekanligini ko‘rsatadi. Mazkur holatlarni erta aniqlash va kompleks davolash jarayoniga psixologik hamda psixiatrik yordamni integratsiya qilish bemorlarning davolanishga moslashuvi va hayot sifatini yaxshilashda muhim ahamiyat kasb etadi
##plugins.themes.default.displayStats.downloads##
Havolalar
1. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 1983;67(6):361–370.
2. Aaronson N.K., Ahmedzai S., Bergman B. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute. 1993;85(5):365–376.
3. Holland J.C., Breitbart W.S., Jacobsen P.B., Loscalzo M.J., McCorkle R., Butow P.N. Psycho-Oncology. 3rd ed. Oxford: Oxford University Press; 2015.
4. Mitchell A.J., Chan M., Bhatti H. et al. Prevalence of depression, anxiety and adjustment disorder in oncological, haematological and palliative-care settings: a meta-analysis. The Lancet Oncology. 2011;12(2):160–174.
5. Mehnert A., Brähler E., Faller H. et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. Journal of Clinical Oncology. 2014;32(31):3540–3546.
6. Pitman A., Suleman S., Hyde N., Hodgkiss A. Depression and anxiety in patients with cancer. BMJ. 2018;361:k1415.
7. Carlson L.E., Angen M., Cullum J. et al. High levels of untreated distress and fatigue in cancer patients. British Journal of Cancer. 2004;90(12):2297–2304.
8. Fayers P.M., Aaronson N.K., Bjordal K., Groenvold M., Curran D., Bottomley A. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Distress Management. NCCN.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. Washington, DC: American Psychiatric Association Publishing; 2022.
